SCHEMBL9906503

SCHEMBL9906503

C=CC(=O)Oc1ccc2cc(C(=O)Oc3ccc(OC(=O)c4ccc5cc(OC(=O)C=C)ccc5c4)c(-c4ccccc4)c3)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.49
MEN1 O00255 6/20 0.49
MAPT P10636 5/20 0.49
TDP1 Q9NUW8 4/20 0.49
CA9 Q16790 3/20 0.41
CA12 O43570 2/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 2/20 0.40
KDM4E B2RXH2 1/20 0.40
EGFR P00533 1/20 0.40
TP53 P04637 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
JAK1 P23458 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9906559 0.91 KMT2A (0.41) KMT2AMEN1MAPTTDP1CA9
SCHEMBL14981342 0.90 KMT2A (0.44) KMT2AMEN1MAPTTDP1CA9
SCHEMBL9906505 0.88 THRB (0.42) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL777890 0.85 KMT2A (0.52) KMT2AMEN1MAPTTDP1CA9
SCHEMBL14981353 0.83 KMT2A (0.53) KMT2AMEN1MAPTTDP1CA9
SCHEMBL16812835 0.82 KMT2A (0.44) KMT2AMEN1MAPTTDP1CA9
SCHEMBL19565624 0.81 KMT2A (0.53) KMT2AMEN1MAPTTDP1CA9
SCHEMBL10783364 0.80 KMT2A (0.50) KMT2AMEN1MAPTTDP1CA9
SCHEMBL12742945 0.80 PTPN7 (0.39) KMT2AMEN1MAPTTDP1SMN1; SMN2
SCHEMBL12742946 0.80 KMT2A (0.40) KMT2AMEN1SMN1; SMN2TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8197710-B2 Polymerizable compound and polymerizable composition ADEKA CORPORATION (JP) 2012-06-12 US disclosed
US-8197710-B2 Polymerizable compound and polymerizable composition ADEKA CORPORATION (JP) 2012-06-12 US disclosed
US-7910021-B2 Polymerizable optical active compound and polymerizable composition containing the same ADEKA CORPORATION (JP) 2011-03-22 US disclosed
US-7910021-B2 Polymerizable optical active compound and polymerizable composition containing the same ADEKA CORPORATION (JP) 2011-03-22 US disclosed
US-20100294990-A1 POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION ADEKA CORPORATION (JP) 2010-11-25 US disclosed
US-20100294990-A1 POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION ADEKA CORPORATION (JP) 2010-11-25 US disclosed
US-20100032620-A1 POLYMERIZABLE OPTICAL ACTIVE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE SAME ADEKA CORPORATION (JP) 2010-02-11 US disclosed
US-20100032620-A1 POLYMERIZABLE OPTICAL ACTIVE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE SAME ADEKA CORPORATION (JP) 2010-02-11 US disclosed
EP-2067796-A1 POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION Adeka Corporation (JP) 2009-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100032620-A1 POLYMERIZABLE OPTICAL ACTIVE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE SAME C1S, PYM1, MCCC2 KMT2A 3291/4885MEN1 360/4885MAPT 51/4885
US-20100294990-A1 POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION PYM1, SCO2, ZYX KMT2A 1150/4885MEN1 255/4885MAPT 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.